Androgen deprivation therapy, commonly called ADT, is a treatment for prostate cancer that works by drastically reducing testosterone and other male hormones (androgens) that fuel prostate cancer growth. It has been a cornerstone of prostate cancer treatment for decades and remains one of the most widely used systemic therapies for the disease. But ADT is not a single treatment so much as a category of approaches, each with trade-offs that ripple through the body in ways many patients don’t expect until they’re living with them.
How Testosterone Drives Prostate Cancer
Prostate cancer cells, like normal prostate cells, depend on androgens to grow and survive. Testosterone and its more potent form, dihydrotestosterone, bind to androgen receptors inside prostate cells. Once activated, these receptors travel into the cell’s nucleus and switch on genes that promote cell division.
1PubMed Central. Androgen receptor-mediated non-genomic regulation of prostate cancer cell proliferation ADT aims to interrupt this chain at various points: by shutting down testosterone production, by blocking the receptor itself, or both. Without androgen signaling, most prostate cancer cells slow their growth or die. The catch is that testosterone does useful work elsewhere in the body, so suppressing it has consequences well beyond the prostate.
Types of Androgen Deprivation Therapy
There are several ways to achieve testosterone suppression, and they fall into a few broad categories.
Surgical Castration
Orchiectomy, the surgical removal of the testicles, is the oldest and most direct form of ADT. Because the testes produce the vast majority of testosterone, the procedure drops levels within hours. It’s permanent, inexpensive, and requires no ongoing medication. Despite those advantages, most patients in practice choose drug-based options, largely because of the psychological impact of the surgery.
GnRH Agonists
These injectable drugs (such as leuprolide and goserelin) work by overstimulating the brain’s signaling pathway that controls testosterone production. After an initial surge, the system essentially shuts down, and testosterone falls to castrate levels within a few weeks. That initial surge, called a “testosterone flare,” can temporarily worsen symptoms in men with advanced disease, so a short course of an antiandrogen pill is often given alongside the first injection to block the flare’s effects.
2PubMed. Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues Randomized trials comparing GnRH agonists with surgical castration have found them equivalent in terms of survival and disease control.3JAMA. Androgen Deprivation Therapy for Prostate Cancer
GnRH Antagonists
GnRH antagonists (such as degarelix and the oral drug relugolix) block the same brain signaling pathway but do so by directly occupying the receptor rather than overstimulating it. The practical difference is that testosterone drops rapidly without the flare seen with agonists.4PubMed. GnRH Antagonists: Current Evidence and Role in Prostate Cancer This makes antagonists attractive for men who have symptoms like spinal cord compression where even a brief testosterone spike could be dangerous. Relugolix, approved in recent years, also offers the convenience of a daily pill rather than injections.
Antiandrogens
Rather than cutting testosterone production, antiandrogen drugs block the receptor that testosterone acts on. Older antiandrogens like bicalutamide were used mainly as short-term add-ons to cover the flare period. Newer, more potent agents like enzalutamide, apalutamide, and darolutamide were designed to inhibit the androgen receptor far more completely and without the partial activation seen with earlier drugs.5PubMed. Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens These second-generation antiandrogens have become central to modern treatment strategies and are now frequently combined with other forms of ADT.
When ADT Is Used
ADT isn’t reserved for one stage of prostate cancer. Its role shifts depending on how advanced the disease is. For localized high-risk prostate cancer, ADT is commonly given alongside radiation therapy. The hormonal treatment sensitizes cancer cells to radiation, and the combination improves survival compared with radiation alone. Early trial data have also shown that combining newer antiandrogens with standard ADT and radiation is safe and may further improve outcomes.6PubMed Central. Combining prostate cancer radiotherapy with therapies targeting the androgen receptor axis
For metastatic hormone-sensitive prostate cancer, meaning disease that has spread but still responds to hormonal manipulation, ADT forms the backbone of treatment. It is increasingly combined with additional agents, which is discussed further below. And for castration-resistant disease, where the cancer has found ways to grow despite low testosterone, second-generation antiandrogens and other drugs are layered on top of continued ADT, because even castration-resistant tumors often retain some degree of androgen dependence.
Cardiovascular and Metabolic Side Effects
Stripping testosterone from the body changes metabolism in ways that increase cardiovascular risk. ADT decreases lean muscle mass and increases body fat. It reduces insulin sensitivity and raises cholesterol and triglycerides.7The Journal of Urology. Metabolic Complications of Androgen Deprivation Therapy for Prostate Cancer These shifts look a lot like metabolic syndrome, and they appear to translate into real increases in diabetes and heart disease.8The Journal of Clinical Endocrinology & Metabolism. Androgen Deprivation Therapy in Prostate Cancer and Metabolic Risk for Atherosclerosis
The cardiovascular risk is not theoretical. A meta-analysis of observational studies found that men on GnRH agonists had roughly a 40% higher risk of nonfatal cardiovascular events compared with prostate cancer patients not on ADT. For heart attacks and strokes specifically, the risk was about 50–60% higher.9PubMed. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis A large Danish population study echoed these findings, showing increased rates of both heart attack and stroke among men on medical hormone therapy.10PubMed. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study Men who already have cardiovascular disease face elevated risk even with short courses of ADT.11PubMed Central. Cardiovascular effects of hormone therapy for prostate cancer
These metabolic and cardiovascular changes are a direct consequence of the severe testosterone deficiency ADT creates.12PubMed. Metabolic and cardiovascular effects of androgen deprivation therapy This is one reason oncologists increasingly coordinate care with cardiologists and primary care physicians, especially for patients who have pre-existing risk factors like high blood pressure, diabetes, or a history of heart disease.
Bone Loss and Fracture Risk
Testosterone plays a protective role in maintaining bone density, and ADT accelerates bone loss at a striking rate. Prospective studies have found that men lose roughly 5–10% of their bone mineral density in just the first year of ADT, a pace several times faster than normal age-related bone loss and even faster than the bone loss women typically experience during menopause.13PubMed Central. Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group This puts men on long-term ADT at substantial risk for osteoporosis and fractures.
Bone-protective medications can blunt this effect. In a large randomized trial, men receiving ADT who were given denosumab, a drug that slows bone breakdown, gained bone density at the lumbar spine over two years instead of losing it. They also had fewer new vertebral fractures at three years, with the fracture rate cut by more than half compared with placebo.14PubMed Central. Denosumab in men receiving androgen-deprivation therapy for prostate cancer Bisphosphonates are another option. Regular bone density screening, calcium, and vitamin D supplementation are standard recommendations for anyone starting ADT.
Other Common Side Effects
Beyond the metabolic and skeletal effects, ADT causes a range of symptoms that affect daily quality of life:
- Hot flashes: One of the most frequently reported complaints, affecting a majority of men on ADT. A randomized trial found that melatonin supplementation reduced the frequency of mild hot flashes within about four weeks, suggesting it may be a low-risk option for relief.15PubMed Central. Targeting Side Effects Associated with Androgen Deprivation Therapy Using Melatonin: A Randomized Trial on Hot Flashes and Sexual Health in Prostate Cancer Patients
- Sexual dysfunction: Loss of libido and erectile dysfunction are nearly universal with ADT because they are direct consequences of very low testosterone.
- Fatigue: Persistent tiredness is common and can be the side effect that most interferes with daily activities.
- Gynecomastia: Breast tissue enlargement and tenderness, particularly with certain antiandrogen regimens.
- Mood changes: Some men experience depression, irritability, or emotional flatness.
Cognitive effects are a particular concern for patients and their families. Some studies using neurocognitive tests have found that ADT may affect certain domains like spatial reasoning and executive function, but the overall evidence is inconsistent. Large database studies have also failed to produce clear-cut conclusions, partly because of the difficulty separating ADT effects from aging, cancer-related stress, and other treatments.16PubMed Central. Androgen deprivation therapy and risk of cognitive dysfunction in men with prostate cancer: is there a possible link? The honest summary is that a cognitive effect likely exists for some men, but researchers have not been able to nail down how large it is or who is most vulnerable.
Exercise as a Countermeasure
If there is a single intervention that addresses the broadest range of ADT side effects, it is structured exercise. A systematic review of trials involving men on ADT found that aerobic and resistance training improved muscular strength, cardiovascular fitness, physical function, lean body mass, and fatigue.17PubMed. Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review Resistance training in particular has been shown to increase muscle size in men on ADT, while a control group that did not exercise lost muscle over the same period.18PubMed Central. Resistance Exercise Training Increases Muscle Mass and Strength in Prostate Cancer Patients on Androgen Deprivation Therapy A pilot trial also found that resistance training improved body composition, strength, and prostate cancer-specific quality of life, with large effect sizes across multiple measures.19PubMed Central. Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial
Given the metabolic, cardiovascular, and musculoskeletal toll of ADT, exercise recommendations are now woven into most clinical guidelines for men starting the therapy. The challenge is practical: many patients are older, may have other health conditions, and often don’t receive clear guidance on what kind of exercise to do or how much. Exercise physiologists or physiotherapists who specialize in oncology can help tailor a program.
Intermittent Versus Continuous ADT
Because of ADT’s cumulative side effects, researchers have studied whether cycling the treatment on and off, known as intermittent ADT, could reduce harm without sacrificing cancer control. The idea is appealing: during off cycles, testosterone partially recovers, and some side effects improve.
The largest randomized trial comparing the two approaches in men with metastatic disease found that intermittent therapy was associated with better erectile function and mental health at three months, though those differences faded over time. Survival was slightly shorter in the intermittent group, with a median of about five years compared with nearly six years for continuous therapy, but the difference was not definitive enough to rule out equivalence.20PubMed Central. Intermittent versus continuous androgen deprivation in prostate cancer A separate randomized trial in metastatic patients also found no significant difference in overall survival or progression-free survival between the two approaches.21PubMed. Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial
In practice, intermittent ADT is most commonly used in non-metastatic settings where the goal is PSA control rather than disease cure. For metastatic disease, continuous therapy remains the more common choice, especially now that combination regimens have improved outcomes substantially.
Combination Therapies and Triplet Regimens
The biggest shift in ADT over the past several years has been the move away from ADT alone for metastatic hormone-sensitive prostate cancer. Today, ADT is almost always combined with at least one additional agent. Adding a second-generation antiandrogen or chemotherapy (docetaxel) to ADT has been shown to extend survival. The frontier has now moved to “triplet” therapy, which adds a third drug to the combination.
The ARASENS trial tested adding darolutamide to ADT plus docetaxel in men with metastatic hormone-sensitive disease. The triplet reduced the risk of death by about a third compared with ADT plus docetaxel alone, and it also delayed progression to castration-resistant disease and slowed pain progression.22Oncology Reviews. Triplet systemic therapy for hormone-sensitive prostate cancer: a critical review with a multidisciplinary approach The PEACE-1 trial similarly found that adding abiraterone to ADT and docetaxel improved both progression-free and overall survival in patients with de novo metastatic disease.23The Lancet. Abiraterone acetate plus prednisone with or without radiotherapy in metastatic hormone-sensitive prostate cancer (PEACE-1) These triplet combinations carry modestly higher toxicity, but the survival gains have been large enough to shift treatment guidelines.
When ADT Stops Working
Most prostate cancers eventually adapt to the low-testosterone environment of ADT, a progression known as castration-resistant prostate cancer. This doesn’t mean the cancer has become completely indifferent to androgens. In many cases, the tumor has found workarounds to reactivate androgen signaling under castrate conditions.
These workarounds are varied. The cancer may amplify the androgen receptor so that even tiny amounts of androgen trigger growth. The receptor itself may mutate, becoming responsive to molecules it normally wouldn’t recognize. Tumors can also produce their own androgens internally, bypassing the need for testicular testosterone. Variant forms of the androgen receptor that don’t require any androgen at all to stay active have also been identified.24PubMed Central. Mechanisms of resistance in castration-resistant prostate cancer (CRPC) Residual hormone levels within cancer cells from internal metabolic pathways also play a role in driving the disease forward.25PubMed Central. Molecular mechanisms of castration-resistant prostate cancer progression
Understanding these resistance mechanisms is what drove the development of second-generation antiandrogens like enzalutamide and androgen-synthesis blockers like abiraterone. Both target the androgen axis more aggressively than traditional ADT alone and have extended survival in the castration-resistant setting. But resistance eventually develops to these drugs too, which is why research continues into new approaches.
Bipolar Androgen Therapy
One of the more counterintuitive ideas in prostate cancer research is bipolar androgen therapy, or BAT. Instead of keeping testosterone permanently suppressed, BAT alternates between periods of very low and very high testosterone. The rationale comes from laboratory observations that a sudden flood of testosterone can actually be toxic to cancer cells that have adapted to a low-testosterone environment.
Clinical studies so far suggest that BAT can be safely given to men with metastatic castration-resistant prostate cancer who have no symptoms. Roughly 30–40% of patients have shown sustained responses in PSA and imaging measures. Perhaps more intriguingly, BAT appears to resensitize tumors to antiandrogen drugs that had previously stopped working, potentially prolonging the response to subsequent therapy.26PubMed Central. Bipolar androgen therapy (BAT): A patient’s guide BAT remains investigational and is not yet standard treatment, but it highlights how much the understanding of androgen signaling in prostate cancer has evolved beyond a simple “more testosterone is bad” model.
Racial Differences in Side Effects
The side effects of ADT do not fall equally across all patients, and emerging research suggests that race plays a role in how the body responds to testosterone suppression. A large study of veterans found that while ADT increased the risk of cardiovascular events, bone fractures, and osteoporosis across all racial groups, the patterns differed. Black patients had a somewhat lower excess risk of cardiovascular events and bone fractures from ADT compared with White patients, but a higher excess risk of osteoporosis.27JAMA Network Open. Racial Differences in Adverse Events After Androgen Deprivation in Veterans With Prostate Cancer
Disparities also show up in how side effects are recognized and managed. A separate study found that after starting ADT, White patients had 30% greater odds of being diagnosed with depression than Black patients. White patients were also more likely to receive a first-line antidepressant.28PubMed. Racial Disparities in Diagnosis and Treatment of Depression Associated with Androgen Deprivation Therapy for Prostate Cancer This doesn’t necessarily mean Black men experience less depression on ADT. It may instead reflect differences in how mood symptoms are screened for, reported, or treated across patient populations. Prostate cancer already disproportionately affects Black men in terms of incidence and aggressiveness, making equitable monitoring of ADT side effects an area that deserves more attention than it currently gets.